Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Easier than A B C. Thanks Trader_3
BBD - Nanoflu is restricted to the influenza A virus (IAV), but does not cover the influenza B virus (IBV), so cannot be described as a universal flu vaccine.
Imutex covers both IAV & IBV viruses, so would be a true universal vaccine.
Apples & Oranges.
Nanoflu reads as a seasonal vaccine here.
Maybe that’s why??
https://www.pharmaceutical-technology.com/news/novavax-nanoflu-influenza/
Is there any reason why everyone is ignoring the NanoFlu vaccine from Novavax in these discussions? It is a different technology, but used to be described as a universal flu vaccine - is that no longer the case? It is well into phase 3 and has fast-track approval from the FDA, so certainly well ahead of flu-V
Yes but the Biondvax valuation last Friday was nowhere near what it was a few months back, it was trading at $62 / share giving it a valuation of about $660 million, that seem bonkers compared to what the whole of OO is worth. Cathal might as well move the OO listing over to Nasdaq and you can multiply our SP x 10 fold on a Peer to Peer valuation I would have thought?
Sorry should of of said moni & dg with there thoughts, GLA
Very true moni, should be an interesting week , plus we have CF on the Proactive investor on Thursday night 6pm 29th oct .
I think it was worth $460M prior to Fridays fall but I could be wrong. So in theory it dropped $400M of which equates to the their level of investment. FX equates to £320M, but you’re right that’s just one trial whereas we have a few more. The Zirus one is another cracker, when the progress of this was announced back in June it made the Lancet and it had zero impact on our share as Acacia were selling into it but the value of a vaccine in this area is worth billions. There’s no doubt we have a few aces in the pack and we have great poker player in CF.
Well if Biondvax was worth $600 million just with one product in development the Flu Drug that has now failed and looks to be almost written off in value terms going by closing SP on Friday? Yet when you look at the sum parts of Open Orphan, i.e it is two companies, Venn life Sciences and Hvivo also with SeeK JV (Imutex 49% share) , plus 62.6% of Prep Biopharm, with loads of new PROFITABLE!!! contracts coming in, yet still only valued as a whole at £160 million. If you compare the value of OO to someone like Biondvax than OO should be worth about £2 billion using exactly the same methods of valuation would you not have thought? I am puzzled, are we due a massive re-rate soon???????? AIMHO so ADYOR!!!
Wondergoals. That is correct, Imutex of which we own 49% has Phase 3 ready Flu-v and Phase 2 ready universal mosquito saliva vaccine. We also own 62.6% of Prep Biopharm which is doing work against covid-19 (can’t remember the technical name) and we also have 100% ownership of repurposed influenza Immune modulator. All have a for sale sign against them and CF has spoken about selling them as a job lot or individually. All have zero value against them, however as a collection they could be worth £500M?? Difficult to put a value but there have been indicators with recent acquisitions of companies with similar trials in that region. At the end of the day it’s only worth what someone is willing to pay but in the current environment there’s definitely been an uptake in value and interest in vaccines. If you get a bidding war then it’s happy days. It’s important to keep our feet on the ground here as we’re not aware yet of any approach but watch this space!
this may help too ...
https://imutex.com/index.php/about/
I assume CF has agreed to sell Imutex with Seek Group?
And in selling Imutex we would also be selling the AGS-v - the mosquito-borne disease vaccine - which I think has successfully met the aims of its phase I trial and could also have positive impact globally.
Seek is not a subsidiary of hVivo
Hvivo owns 49% of Seek group who have flu v.
Interest thought. just checking out Biondvax valuation, it looks like it was trading at about $60 a share a while ago valuing the company circa $600 million on nasdaq. From what I can make out it doesn't make a profit (not sure), has about 20 staff and and one product in development (check this out for yourselves to be 100% sure as info quite hard to confirm).... So what's this going to make Imutex worth on its own (not including the whole OO organisation) if all the attention now comes in the Flu-v vaccine direction? just remember Imutex is currently valued at a big fat zero on OO's balance sheet. I assume come Monday it's could potentially be worth one hell of a lot more if all the US investors shift their sights over here. here are some useful links to check out to research...I did post a link further down about Flu-v which is also worth a read.....ADYOR!!!!!!!!!!!!
http://www.biondvax.com/about-us/
http://www.biondvax.com/2020/10/biondvax-announces-topline-results-from-phase-3-clinical-trial-of-the-m-001-universal-influenza-vaccine-candidate/
https://finance.yahoo.com/quote/BVXV?p=BVXV&.tsrc=fin-srch
25/10/2020
09:57 pierre oreilly: I think the pretty obvious fact about the other companies flu thing failing is that it is bad for mankind, but good for orph. It obviously increases the value of any competing drug possibilities for those still left in the game. I think the only one having jumped the phase 2 hurdle is Seek's, half owned by immutex, fully owned by orph. Maybe our christmas pressy has gone up 20% from last week. Did I imagine it or did C say that our flu drug has had 3 successful challenge studies already, so another one isn't planned?
Interesting post on ADVFN.
I would also concur that we have already done successful Phase 2 CS ..How do you value Imutex now ?